Overexpression of TPD52L2 in HNSCC: prognostic significance and correlation with immune infiltrates

被引:0
|
作者
Lu, Min [1 ]
Xia, Haoyu [2 ]
Xu, Jing [1 ]
Liao, Zijun [1 ]
Li, Yuwen [1 ]
Peng, Hanwei [1 ]
机构
[1] Shantou Univ, Dept Head & Neck Surg, Canc Hosp, Med Coll, Shantou 515041, Guangdong, Peoples R China
[2] Shantou Univ, Canc Hosp, Med Coll, Dept Gynecol Oncol, Shantou 515041, Guangdong, Peoples R China
来源
BMC ORAL HEALTH | 2024年 / 24卷 / 01期
关键词
Head and neck squamous carcinoma; Diagnosis; Prognosis; Immune cells; Bioinformatics; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; HEAD; CANCER; DIAGNOSIS; PROLIFERATION; MIGRATION; TP53;
D O I
10.1186/s12903-024-04977-1
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BackgroundEvidence has been presented that the tumor protein D52 (TPD52) family plays a critical role in tumor development and progression. As a member of the TPD52 family, the changes in TPD52L2 gene status are instrumental in kinds of cancer development. However, its effects on patient prognosis and immune infiltration in Head and Neck Squamous Carcinoma (HNSCC) are still poorly understood.MethodsThe Tumor Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and c-BioPortal database was used to explore the expression pattern, prognostic value, and variation of gene status in HNSCC. The LinkedOmics database was used to obtain the co-expression genes of TPD52L2 and identify the diagnostic value of TPD52L2 in HNSCC. The correlations between TPD52L2 expression and six main types of immune cell infiltrations and immune signatures were explored using Tumor Immune Estimation Resource (TIMER). The correlation between TPD52L2 expression and immune checkpoint genes (ICGs) was analyzed by TCGA database. Immunohistochemistry (IHC) was performed to validate the expression of three ICGs (PDL1, PDL2, EGFR) and TPD52L2 using 5 paired HNSCC and normal head and neck tissues. Polymerase Chain Reaction (PCR) and Western Blot (WB) of HNSCC and normal head and neck cell lines were performed to verify the high level of TPD52L2 mRNA and protein expression. protein expression of TPD52L2 in pan-cancer was also validated using UALCAN.ResultsTPD52L2 was overexpressed in tumor tissues, and it predicted worse survival status in HNSCC. ROC analysis suggested that TPD52L2 had a diagnostic value. Multivariate Cox analysis identified TPD52L2 as an independent negative prognostic marker of overall survival. Functional network analysis suggested that TPD52L2 was associated with immune-related signaling pathways, cell migration pathways, and cancer-related pathways. High expression of TPD52L2 was associated with a more mutant frequency of TP53. Notably, we found that the expression of TPD52L2 was closely negatively correlated with the infiltration levels of 15 types of immune cells and positively correlated with several immune markers. PCR, WB experiments, and UALCAN database verified the high level of TPD52L2 mRNA and protein expression.ConclusionTPD52L2 is upregulated in HNSCC, which is an independent factor for adverse prognosis prediction. It probably plays a role in the negative regulation of immune cell infiltration. TPD52L2 might be a promising prognostic biomarker and therapeutic target in HNSCC.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Prognostic Implications of the Complement Protein CIQ and Its Correlation with Immune Infiltrates in Osteosarcoma
    Huang, Hanji
    Tan, Manli
    Zheng, Li
    Yan, Guohua
    Li, Kanglu
    Lu, Dejie
    Cui, Xiaofei
    He, Si
    Lei, Danqing
    Zhu, Bo
    Zhao, Jinmin
    ONCOTARGETS AND THERAPY, 2021, 14 : 1737 - 1751
  • [32] A tumor-suppressive microRNA, miRNA-485-5p, inhibits glioma cell proliferation and invasion by down-regulating TPD52L2
    Yu, Jin
    Wu, Shi-Wen
    Wu, Wei-Ping
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (07): : 3336 - 3344
  • [33] TPD52 is a Potential Prognostic Biomarker and Correlated with Immune Infiltration: A Pan-cancer Analysis
    Miao, Lu
    Jing, Li
    Chen, Buze
    Zeng, Tian
    Chen, Youguo
    CURRENT MOLECULAR MEDICINE, 2024, 24 (11) : 1413 - 1425
  • [34] LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma
    Fan, Longfei
    Qin, Zhongqiang
    Wu, Di
    Yang, Yunchuan
    Zhang, Yigang
    Xie, Bo
    Qian, Jingyu
    Wei, Jianzhu
    Wang, Zhaoying
    Yang, Peipei
    Qian, Zhen
    Yuan, Mu
    Zhu, Ziyi
    Tan, Yulin
    Tan, Yi
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 2203 - 2221
  • [35] JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer
    Chen, Bo
    Lai, Jianguo
    Dai, Danian
    Chen, Rong
    Li, Xuan
    Liao, Ning
    AGING-US, 2019, 11 (23): : 11124 - 11135
  • [36] Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma
    Luan, Hong
    Zhang, Chuang
    Zhang, Tuo
    He, Ye
    Su, Yanna
    Zhou, Liping
    DISEASE MARKERS, 2020, 2020
  • [37] Prognostic Biomarker SPOCD1 and Its Correlation with Immune Infiltrates in Colorectal Cancer
    Gan, Lin
    Yang, Changjiang
    Zhao, Long
    Wang, Shan
    Gao, Zhidong
    Ye, Yingjiang
    BIOMOLECULES, 2023, 13 (02)
  • [38] Prognostic value of RNF113A shows a correlation with immune infiltrates in colorectal cancer
    Chen, Minghui
    Song, Xiaoyu
    Lin, Huizhen
    Cheng, Wenli
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (04): : 1281 - 1294
  • [39] KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
    Zhu, Hongyuan
    Yu, Yunfang
    Zheng, Yating
    Xu, Bin
    Zheng, Shaopeng
    Zeng, Fanjun
    Xie, Wenzhuan
    Huang, Luyu
    Li, Fasheng
    Lin, Weihuan
    Liao, Guoqing
    Wu, Shaowei
    Liu, Xinyi
    Huang, Mengli
    Zhou, Haiyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] ALDH2 is a prognostic biomarker and related with immune infiltrates in HCC
    Yao, Senbang
    Yin, Xiangxiang
    Chen, Tingting
    Chen, Wenjun
    Zuo, He
    Bi, Ziran
    Zhang, Xiuqing
    Jing, Yanyan
    Pang, Lulian
    Cheng, Huaidong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (11): : 5319 - +